Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C15H17BrN2O5.Tc |
| Molecular Weight | 869.326 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[99Tc+4].CC1=CC(C)=C(NC(=O)CN(CC([O-])=O)CC([O-])=O)C(C)=C1Br.CC2=CC(C)=C(NC(=O)CN(CC([O-])=O)CC([O-])=O)C(C)=C2Br
InChI
InChIKey=MGKWQLBBVFGWLJ-FCHARDOESA-J
InChI=1S/2C15H19BrN2O5.Tc/c2*1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h2*4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/q;;+4/p-4/i;;1+1
| Molecular Formula | C15H17BrN2O5 |
| Molecular Weight | 385.21 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Tc |
| Molecular Weight | 98.906254554 |
| Charge | 4 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.hindawi.com/journals/stni/2014/839369/Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/books/NBK215133/ | https://www.iaea.org/OurWork/ST/NE/NEFW/Technical-Areas/RRS/documents /mo99/WORKINGMATERIALSmo99CM.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27854401
Sources: https://www.hindawi.com/journals/stni/2014/839369/
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/books/NBK215133/ | https://www.iaea.org/OurWork/ST/NE/NEFW/Technical-Areas/RRS/documents /mo99/WORKINGMATERIALSmo99CM.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27854401
Molybdenum-99 (99Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (half-life = 6 h), which is used in over 30 million procedures per year around the world. Between 95 and 98 percent of Mo-99 is currently being produced using highly enriched uranium (HEU) targets. Other medical isotopes such as iodine-131 (I-131) and xenon-133 (Xe-133) are by-products of the Mo-99 production process and will be sufficiently available if Mo-99 is available.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | OSTEOLITE Approved UseUnknown Launch Date1977 |
|||
| Diagnostic | DRAXIMAGE MDP-10 Approved UseMDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date1978 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:19 GMT 2025
by
admin
on
Mon Mar 31 18:07:19 GMT 2025
|
| Record UNII |
F2NQ468L52
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2124
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
||
|
NDF-RT |
N0000177914
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
||
|
NDF-RT |
N0000000205
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
||
|
WHO-ATC |
V09DA04
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
F2NQ468L52
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
C80064
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
11431716
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
SUB15472MIG
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
DB09137
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
100000091048
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
Technetium Tc 99m Mebrofenin
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110555
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY | |||
|
5119
Created by
admin on Mon Mar 31 18:07:19 GMT 2025 , Edited by admin on Mon Mar 31 18:07:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 ?M) to 4% of control
|
||
|
TRANSPORTER -> SUBSTRATE |
MRP3-mediated transport was inhibited to 5% of control by estradiol-17-beta-glucuronide (100 ?M).
|
||
|
TRANSPORTER -> SUBSTRATE |
MEB (0.4 nM) transport by MRP2 was inhibited to 12% of control by MK571 (50 ?M).
|
||
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TRANSPORTER -> SUBSTRATE |
MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 ?M) to 10% of control
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Diagnostic radiopharmaceutical used for imaging of the liver and the gallbladder.
|